posted
I got this article sent to me from the mycoplasma group on yahoo. Supposedly they came out with Injectable Doxycycline that last in the body for 19 days. Also a patch. Im curious if anybody has heard of this? I cant tell if its out for distribution yet or what.
here is the article:
Editorial: Need to Fast Track "Injectable Doxycycline" & "Doxycycline Skin Patch" by Leslee Dudley & Sean Dudley � 2008 All rights reserved.
The antiboitc doxycycline is an effective treatment for both Mycoplasma fermentans infections and Lyme Disease. One of the problems with oral doxycycline is that the pill form can be distoryed when combined with certain foods and medications in the stomach, therefore the drug does not get into the blood stream to treat infections, causeing treatment failure. Another problem is that patients need monitoring by their physicians during long-term oral doxycycline treatment for digestive system and liver side effects.
Now a long-acting "non-oral" doxycycline has been developed by Nordin Zeidnerhopes and a Fort Collins company, QLT. Its an injectable doxycycline that could be sustained in the body for 19 days. An injectable doxycycline would bypass the digestive system and deliver the drug directly into the blood stream, increasing treatment success and eliminating digestive system side effectives . An injectable doxycycline would be more practical and less expensive that IV antibiotics that are used on Rheumatoid Arthritis and autoimmune diseases patients with mycoplasmal infections and Lyme Disease patients. A long acting injectable doxycycline might even cut down treatment time.
Nordin Zeidnerhopes also hopes to develop a doxycycline skin patch too. We hope that both these new delivery forms of doxycycline will be quickly developed and fast tracked for patients use.
Have We Finally Found an Effective Defense Against Lyme Disease? A new treatment may block transmission 85 percent of the time. by Pamela Weintraub Discover Magazine - New York,NY,USA - July 9, 2008 effective-defense- against-lyme- disease>
With patients complaining that standard antibiotic treatment can leave lingering symptoms, Lyme disease has long been mired in controversy. Now a new, long-acting preparation of the antibiotic doxycycline may help prevent Lyme and another tickborne infection.
Researchers at New York Medical College (NYMC) had tried using doxycycline as a Lyme preventive, reporting that a single oral dose could block transmission 85 percent of the time. But immunologist Nordin Zeidner, chief of the Centers for Disease Control and Prevention's Vector-Host Laboratory in Fort Collins, Colorado, had doubts, and after retesting the technique found a success rate of just 20 to 30 percent in mice.
Zeidner thought the problem was the single oral dose of the antibiotic, so he asked a Fort Collins company, QLT, to develop a form of injectable doxy that could be sustained in the body for 19 days. Trying it on mice, Zeidner found that 100 percent were protected from Lyme as well as anaplasmosis. Now he plans to study the approach in humans and hopes to develop a doxy skin patch that will last for an entire tick season.
Gary Wormser, an author of the NYMC study, meanwhile, counters that single-dose doxy should be more effective in humans than in mice because it stays in our blood longer.
The Lyme Disease Network is a non-profit organization funded by individual donations. If you would like to support the Network and the LymeNet system of Web services, please send your donations to:
The
Lyme Disease Network of New Jersey 907 Pebble Creek Court,
Pennington,
NJ08534USA http://www.lymenet.org/
UBBFriend: Email this page to someone!
![[Frown]](frown.gif)
Printer-friendly view of this topic